RCC, also referred to as kidney cancer, develops in the kidney’s tubules, which are where urine is produced and waste is removed from the circulation. Immune checkpoint inhibitors (ICIs), such as programmed death-1 (PD-1) blockers (pembrolizumab and nivolumab), are frequently used as first-line treatments for RCC patients. However, a large number of patients relapse or do not benefit from ICI therapies. The high degree of ICI failure among RCC patients presents an immediate need to seek additional therapeutic strategies demonstrating both safety and efficacy in patients previously treated with immunotherapy. A team of researchers recently tested one such therapeutic regimen and published the results of their study in The Lancet Oncology.